1. Home
  2. REPL vs THQ Comparison

REPL vs THQ Comparison

Compare REPL & THQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$10.17

Market Cap

721.7M

Sector

Health Care

ML Signal

HOLD

Logo abrdn Healthcare Opportunities Fund Shares of Beneficial Interest

THQ

abrdn Healthcare Opportunities Fund Shares of Beneficial Interest

HOLD

Current Price

$18.73

Market Cap

753.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
REPL
THQ
Founded
2015
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
721.7M
753.1M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
REPL
THQ
Price
$10.17
$18.73
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
1.7M
158.9K
Earning Date
11-06-2025
01-01-0001
Dividend Yield
N/A
7.53%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.68
$15.29
52 Week High
$14.80
$20.38

Technical Indicators

Market Signals
Indicator
REPL
THQ
Relative Strength Index (RSI) 61.36 56.58
Support Level $9.35 $18.30
Resistance Level $11.09 $18.94
Average True Range (ATR) 0.60 0.29
MACD -0.08 -0.04
Stochastic Oscillator 53.32 39.07

Price Performance

Historical Comparison
REPL
THQ

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest

abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. The fund's investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies.

Share on Social Networks: